glp-1 drugs fda approved medicare part d coverage 2025 covers GLP-1s for $50/month starting July 2026 Navigating Changes to GLP-1 Medication

The growth in the forecast period can be attributed to growing obesity population, expanding approval for cardiovascular risk reduction, innovation in oral and combination therapies, increased penetration in emerging markets, rising patient preference for weight loss benefits

What the research found by the numbers Here are the specific, quantitative results the studies below produced

[DOI] [PMC free article] [PubMed] [Google Scholar] 195.Kane R.M., Nicklas J.M., Schwartz J.L., Bramante C.T., Yancy W.S., Jr., Gudzune K.A., Jay M.R

Despite a significant number of bills in 2023 and 2024 that would have required mandated coverage of GLP-1s in Medicaid, state employee health plans, or for health insurers regulated by the state, only Arkansas, California, Maryland, New Mexico, Pennsylvania, and Texas have introduced legislation mandating coverage in 2025 to date

The use of GLP-1 analogues in such cases could be a pragmatic approach based on prescribing information, available clinical evidence and clinical sense of physicians (Grade D